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A B S T R A C T
Background & aims: Gaucher disease (GD) is a multisystemic disease. Liver involvement in GD is not well
characterised and ranges from hepatomegaly to cirrhosis and hepatocellular carcinoma.We aim to describe, and
assess the effect of treatment, on the hepatic phenotype of a cohort of patients with GD types I and II.
Methods: Retrospective study based on the review of the medical files of the Gaucher Reference Centre of the
Hospital de Clínicas de Porto Alegre, Brazil. Data from all GD types I and III patients seen at the centre since 2003
were analysed. Variables were compared as pre- (“baseline”) and post-treatment (“follow-up”).
Results: Forty-two patients (types I: 39, III: 3; female: 22; median age: 35 y; enzyme replacement therapy: 37;
substrate reduction therapy: 2; non-treated: 3; median time on treatment-MTT: 124 months) were included.
Liver enzyme abnormalities, hepatomegaly, and steatosis at baseline were seen in 19/28 (68%), 28/42 (67%),
and 3/38 patients (8%), respectively; at follow-up, 21/38 (55%), 15/38 (39%) and 15/38 (39%). MRI iron
quantification showed overload in 7/8 patients (treated: 7; MTT: 55 months), being severe in 2/7 (treated: 2/2;
MTT: 44.5 months). Eight patients had liver biopsy (treated: 6; MTT: 58 months), with fibrosis in 3 (treated: 1;
time on treatment: 108 months) and steatohepatitis in 2 (treated: 2; time on treatment: 69 and 185 months). One
patient developed hepatocellular carcinoma.
Conclusions: GD is a heterogeneous disease that causes different patterns of liver damage even during treatment.
Although treatment improves the hepatocellular damage, it is associated with an increased rate of steatosis. This
study highlights the importance of a follow-up of liver integrity in these patients.
1. Introduction
Gaucher disease (GD) (OMIM #230800, #230900 and #231000) is
an autosomal recessive disorder most frequently caused by biallelic
pathogenic variants in the GBA1 gene that codes for glucocerebrosidase
(GCase). The impaired activity of GCase causes glucosylceramide
(GlcCer) to build up into the lysosomes of the reticuloendothelial
system cells, mainly macrophages that become engorged and dysfunc-
tional being thus called “Gaucher cells” [1]. The incidence of GD ranges
between 1:50,000 and 1:100,000 in the general population, and is
about 1:855 in the Ashkenazi Jewish population [2]. GD is broadly
categorised in three types, according to neurological manifestations:
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type I, or “non-neuronopathic”; type II, or “acute neuronopathic”; and
type III, or “chronic neuronopathic”.
The manifestations of GD are multisystemic with a complex pa-
thophysiologic process that arises from the infiltration of organs by
Gaucher cells, the low-grade inflammation promoted by cells whose
intracellular signalling is disrupted by the accumulation of GlcCer
[3,4], and other factors such as aberrant complement activity [5,6] and
dysfunctional autophagy [7,8]. The main signs and symptoms of GD
include hepatosplenomegaly, anaemia, thrombocytopenia, bone defor-
mities and pain, osteonecrosis, restrictive pulmonary disease, and
neurological compromise in patients with GD type II and III [1,2] which
cause significant impairment in life quality and reduction of life ex-
pectancy [9,10]. Treatment of GD is currently available in two mod-
alities: enzyme replacement therapy (ERT) and substrate reduction
therapy (SRT). The former is the most established treatment, consisting
in the fortnightly infusion of recombinant GCase which is uptaken by
the macrophages' lysosomes, decreasing the GlcCer build-up [1,2,11].
Imiglucerase (Sanofi Genzyme Corporation, Cambridge, MA, USA), ta-
liglucerase alfa (Protalix Biotherapeutics, Carmiel, Israel), and ve-
laglucerase alfa (Takeda Pharmaceutical Company, Tokyo, Japan) are
the currently available enzymes with no detectable difference in effi-
cacy or safety profile known between them [1,12, 13–16]. SRT is ad-
ministered orally once or twice daily and works decreasing the pro-
duction of GlcCer which consequently decreases its storage [17]. The
currently SRT FDA-approved compounds are miglustat and eliglustat.
ERT and/or SRT are not indicated for GD type II patients.
The extent of liver damage in GD is still subject of debate – first
reports were limited to hepatomegaly, however it is currently known
that patients are at increased risk for focal fibrosis, cholelithiasis,
steatosis, haemosiderosis, overt cirrhosis, and hepatocellular carcinoma
(HCC) [18,19]. Recent studies [20,21] have shown that liver stiffness is
increased in a large proportion of patients with GD, suggesting that
fibrosis may be a pervasive process even in patients with apparent
controlled disease, and also that it is correlated to disease severity,
making it an important cause of morbidity to be addressed in this po-
pulation.
In this study, we aimed at characterising the liver involvement in a
cohort of patients with GD type I and III, and the effect of ERT/SRT on
those variables.
2. Methods
This is a retrospective study, based on the review of the medical
records of the GD types I and III patients followed at the Gaucher
Reference Centre of the Hospital de Clínicas de Porto Alegre, Brazil
(GRC-HCPA) from 2003 to 2018. HCPA is a public, university hospital
located in Southern Brazil. Inclusion criteria were: a) having bio-
chemical or genetic diagnosis of GD; b) not having any other primary
liver disease, as determined by clinical and laboratory features and
serological screening for hepatitis B and C.
At the GRC-HCPA, patients have regular appointments every
3–4 months and most exams are made in an annual basis unless an
acute event prompts a more frequent evaluation. The following exams
were performed at baseline for most patients: complete blood count,
chitotriosidase activity, aspartate-transaminase (AST), alanine-transa-
minase (ALT), and abdominal ultrasonography (US). The following
exams are performed yearly: AST, ALT, γ-glutamyltransferase (γGT),
direct bilirubin (DB), indirect bilirubin (IB), prothrombin time, alkaline
phosphatase, total and fractional cholesterol, triglycerides, serum
creatinine, blood urea, calcium, phosphorus, US, serum protein elec-
trophoresis, serum immunoglobulins, transferrin saturation/iron-
binding capacity, and serum iron. The following exams are performed
every three months: complete blood count, serum ferritin, and chito-
triosidase activity. All patients are tested for serological markers of viral
hepatitis at initiation of treatment and again according to clinical in-
dication. Alpha-foetoprotein (AFP) is not ordered for patients without
cirrhosis due to its dubious efficacy as a screening test for hepatocel-
lular carcinoma [22]. The presence of hepatomegaly was ascertained by
US or by physical exam (when US was not available). The presence of
steatosis was assessed by US. Elastography for fibrosis assessment is not
routinely performed. Other exams are performed according to clinical
indication [23]. All patients had genotyping of GBA and HFE by next-
generation sequencing.
Immunological and iron metabolism findings of our cohort have
already been described by Vairo et al. [24] and Koppe et al. [25], re-
spectively.
Statistical analyses were performed using the SPSS software (IBM
Inc., v.18); for comparison of frequencies of categorical variables, the
χ2 test was used. Patients were compared regarding the findings before
the onset of treatment (“baseline” data points) and during treatment
until last follow-up (“follow-up” data points). Findings were considered
abnormal at baseline or at follow up if altered in at least two mea-
surements for each datapoint, or one measurement when it was the only
one available.
3. Ethics statement
This study was approved by the Institutional Review Board of HCPA
(CEP/HCPA), Porto Alegre, RS, Brazil (projects #13–0537 and
#15–0083). All studies were conducted according to the Declaration of
Helsinki. Written informed consent was obtained from all subjects or,
when <18 years-old, from their parents.
4. Results
4.1. Subjects
Forty-two patients were included (n = 39, type I; n = 3, type III;
female = 22; median time on treatment: 124 months). One patient with
GD type I (pt 26D) was excluded from the follow-up data analysis due to
diagnosis of active chronic hepatitis B. One patient with GD type I (pt
26A) had serological evidence of spontaneously cured hepatitis B. No
other patients had signs of other liver diseases, such as drug-related
liver injury, autoimmune hepatitis, or viral hepatitis.
No patient had a history of blood transfusions in the past. A total of
36 patients had measurements of serum transferrin saturation after
treatment; of these, 6 had decreased values and 5 had increased values
(Supplementary Table 1). Four patients had used ferrous sulphate
supplements in the past, one of them only during pregnancy
(Supplementary Table). No patient was homozygous or compound
heterozygous for pathogenic variants in the HFE gene, ruling out the
concomitant diagnosis of HFE-associated haemochromatosis (MIM:
#235200).
4.2. Laboratory findings
Laboratory findings of all patients are shown in Table 1
Out of the 28 patients with liver enzymes (AST, ALT, or γGT) data at
baseline, 19/28 (68%) had abnormal liver enzymes in at least two
measurements. At follow-up, 21/38 (68%) had abnormalities in at least
one liver enzyme in at least two measurements. History was positive for
excessive alcohol intake in two patients (19B and 26B).
Serum transferrin saturation, immunoglobulins, and serum protein
electrophoresis results during treatment can be found in the supple-
mentary table. Immunoglobulin measurements and serum protein
electrophoresis results were available for 36 patients during treatment;
of these, 26 had an abnormal serum immunoglobulin measurement at
least twice and 20 had increased γ-globulins in serum electrophoresis at
least twice.
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4.3. Liver ultrasound findings
Liver US reports were available from 39 patients (baseline = 39;
follow-up = 38) (Tables 2 and 3). Hepatomegaly was present in 28/42
(67%) of patients at baseline and in 15/38 (39%) of patients at follow-
up.
Steatosis was present in 3/39 (8%) of patients at baseline and in 15/
38 (39%) at follow-up. In 6 patients, there was regression of steatosis
within 2 years of US detection. Of these, none had any significant
change in body-mass index (BMI) but two had changes in the ERT re-
gimen (for patient 15, there was an increase in the imiglucerase dosage
from 45 IU/Kg to 60 IU/Kg; for patient 19C, there was a switch from
taliglucerase alfa to imiglucerase). Twelve out of the 16 patients (75%)
with steatosis were overweight or obese, with 4 patients (two whose
steatosis regressed, one that maintains the finding, and one that denied
treatment and further follow-up) having a normal BMI. A significant
difference was found between the frequency of overweight/obesity in
patients with and without persistent steatosis (77.8% vs 40%, p= .047,
Pearson's χ2). Blood lipid levels were available for 7 of the 9 patients
(78%) with non-regressing steatosis during treatment. All 7 patients
had dyslipidaemia (four with high triglycerides, three with high total
cholesterol and LDL, and five with low HDL). Levels were available for
31 patients without non-regressing steatosis – of these, 28 (90.3%) had
dyslipidaemia (10 with high triglycerides, 5 with high total cholesterol
and LDL, and 25 with low HDL). No significant difference was found
between patients with and without non-regressing steatosis and the
presence of dyslipidaemia (p = .814, Pearson's χ2).
Twelve patients in the cohort had cholelithiasis, and 7 of them
underwent cholecystectomy (pts. 13, 18, 19A, 20, 23, 25A, and 25B).
Patient 23 had cholecystectomy before initiation of treatment for GD.
Eight out of the patients with cholelithiasis were overweight or obese,
but no significant difference in the prevalence of overweight/obesity
was found between the patients with and without cholelithiasis (66.7%
vs 40.7%, p = .135, Pearson's χ2).
Other US findings observed in the cohort were: cysts, haemangioma,
solid nodule compatible with an adenoma or a haemangioma, portal
hypertension that resolved with initiation of ERT, and cirrhosis with
HCC. The two cysts of unknown diagnosis were present in a pair of
brothers with GD type I who also had steatosis (pts 29A and 29B). The
older brother passed away at the age of 65 due to multiple myeloma.
The cyst in the younger brother, now aged 65, is 5 mm in diameter and
is stable since it was diagnosed 2 years ago. The patient with cirrhosis
Table 2
US findings from GD patients at baseline.
Patient Age
(y)
BMI Steatosis Hepatomegaly Cholelithiasis Ferritin
(ng/dL)
MetSa Liver biopsy
1A 7 15.9 No No No 378 No No
1B 8 16.1 No Yes No – No No
2 1 16.9 No Yes No – No No
3 15 17.3 Yes No No 174.6 No No
4A 16 21.8 No No No 284.8 No No
4B 26 22.7 Yes Yes Yes 328.5 No No
5 8 15.1 No Yes No – No No
6 20 22.6 No Yes No 219.3 No Yes
7 6 14.6 No Yes No – No No
8 7 12 No Yes No 97.3 No No
9 17 18.3 No Yes No 166 No No
10 9 14.5 No Yes No – No No
11A – 14.1 – Yes No – No No
11B – – – Yes No – No No
12 12 17.3 No No No – No No
13 14 23 No No No – No No
14 6 16.2 No Yes No – No No
15 11 12.5 No Yes No – No No
16 – 15.2 – Yes No – No No
17 24 16.8 No Yes No – No No
18 17 21.6 No Yes No – No No
19A 39 30.2 No Yes Yes 758.3 No No
19B 28 22.2 No Yes No – No No
19C 43 26.5 No No No 951.8 No No
20 18 21.9 No Yes No – No No
21 13 16.6- No Yes No – No No
22A 30 24 No Yes No 469.6 No No
22B 29 23.2 No Yes No 213.3 No No
23 34 25.3 No No No 835 Yes Yes
24 22 24.3- No No No – No No
25A 42 23.4 No Yes Yes 754.2 No No
25B 43 30.2 Yes Yes Yes 860.7 No No
26A 44 25 No No No 811 No No
26B 50 31.4 No No No 1409 Yes No
26C 57 23.5 No No No 1593 No No
26D 34 19.3 No Yes No – No No
27 44 – No Yes No – No No
28 52 24 No Yes No 3392 Yes Yes
29A 55 28.5 No No Yes 1698 Yes No
29B 61 27.2 No No Yes 778.2 No No
30 60 29.8 No Yes No 1972 Yes No
31 62 17.7 No No No 1343 No No
y = years-old; US = ultrasonography; BMI = body-mass index; MetS = metabolic syndrome. Ferritin RV <150 ng/dL for women, <300 ng/dL for men.
a Metabolic syndrome is defined as the presence of at least three of the following: obesity, high triglycerides level, increased blood pressure, and elevated fasting
blood glucose (reduced HDL level was not considered as a criterion because it is a feature of GD).
R.T. Starosta, et al. Molecular Genetics and Metabolism Reports 22 (2020) 100564
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(pt 28) is a 62-year-old male splenectomised GD type I patient de-
scribed elsewhere 26.
4.4. Magnetic resonance iron quantification
Liver iron quantification by magnetic resonance had been
performed in 7 patients with GD type I on treatment with ERT
(Table 4). Iron overload was observed in 6/7 (85%) patients, ranging
from 50 to 280 μmol/g (reference value (RV): <36). All the patients
with iron overload had high ferritin values, ranging from 244 to
3011 ng/mL. Two patients had a high level of iron overload
(>79 μmol/g [27]) – one was a 55-year-old male patient whose MRI
Table 3











1A – T(7) – No – 17.4 308 No No
1B 20 I(168) No No No 28.6 485 No No
2 20 I(110) T(1) V(81) Yesb Yes Yes 21.7 254 No No
3 – – – – – – – – –
4A – – – No No 24.4 312.2 No No
4B 36 I(19) T(1) I(89) No Yes Yes 25.9 57.3 No No
5 22 I(177) No No No 22.7 84.7 No No
6 23 T(33) No No No 22.4 172.6 No No
7 17 I(68) No No No 19.2 885.3 No No
8 25 I(156) Yesb Yes No 20.5 508.3 No No
9 26 I(112) No No No 22.7 94.6 No No
10 25 I(200) No Yes No 24.7 547 No No
11A 26 I(174) Yes Yes Yes 18.8 242.6 No No
11B 28 I(146) No Yes No 27.8 285.9 No No
12 25 I(126) No Yes No 23.1 546.3 No No
13 27 I(120) T(1) I(6) E(41) I(8) E(9) Noc No Yes 28.8 611.6 No Yes
14 23 I(189) No Yes No 24.9 619.9 No No
15 29 I(216) Yesb Yes No 26.6 311.1 No No
16 25 A(31) I(222) No No No 20.6 569.8 No No
17 29 I(109) T(2) I(9) T(55) No No No 30.6 325.8 No No
18 33 M(7) I(111) No Yes Yes 25.3 278.8 Yes No
19A 45 I(67) Yesb No Yes 32 66.5 No No
19B 34 I(71) No No No 27.8 585.3 No No
19C 51 I(6) T(1) I(80) Yesb Yes No 28.3 1084 Yes No
20 36 I(207) No No Yes 25.6 574.2 No No
21 32 A(25) I(28) T(3) I(4) No No No 22.7 415.7 No No
22A 36 I(5) T(65) No Yes No 26.8 463.8 No No
22B 40 I(22) T(2) I(14) E(70) Yes No No 30 32 Yes No
23 38 I(35) Yesb No Yes 30.7 427.2 No No
24 44 I(102) T(3) I(29) T(38) No Yes No 28.7 247.9 No No
25A 48 M(11) T(1) I(55) Yes No Yes 25.8 611.9 No Yes
25B 51 M(30) T(10) Yes No Yes 31.9 1053 No Yes
26A 52 I(80) No No No 24.1 480.6 No No
26B 58 I(76) Yes No No 32.2 1457 Yes Yes
26C 62 I(66) No No No 21.6 624.8 No No
27 61 I(124) T(2) I(8) T(71) Yes No No 26.6 1052 Yes No
28 62 I(34) T(2) I(88) No No No 22.3 543.2 No Yes
29A 65 I(10) T(2) I(9) T(81) Yes No Yes 34.5 670 Yes No
29B 65 I(19) T(2) I(8) T(14) Yes Yes Yes 29.7 686 Yes No
30 67 I(12) M(25) I(47) No Yes No 30.5 1103 Yes Yes
31 – – – – – – – – –
y = years-old; BMI = body mass index; I = imiglucerase; T = taliglucerase alfa; V= = velaglucerase alfa; E = eliglustat; A = alglucerase; M = miglustat.
a Metabolic syndrome is defined as the presence of at least three of the following: obesity, high triglycerides level, increased blood pressure, and elevated fasting
blood glucose (reduced HDL level was not considered as a criterium because it is a feature of GD).
b Steatosis regressed within two years of US detection.
c Steatosis at liver biopsy only.
Table 4
Patients screened for hepatic iron overload with magnetic resonance.
Patient Age (y) Gender HFE genotype Ferritin (ng/dL) Transferrin saturation Treatment at exam Time on treatment (months) Iron concentration (μmol/g)
10 26 M p.Cys282Tyr/wt 525 – I I(196) 70
15 24 F wt/wt 298.4 30.7% I I(160) 50
23 34 F p.His63Asp/wt 835 25% None – 5
25A 44 F p.His63Asp/wt 937.1 50.8% I M(11) T(1) I(8) 55
26B 55 M p.Cys282Tyr/wt 1813 47.2% I I(55) 280
27 59 F wt/wt 347 44% T I(124) T(2) I(8) T(41) 65
30 63 F wt/wt 3011 17.4% M I(12) M(22) 210
All patients are type I. Ferritin and transferrin saturation values given are approximately from the time of the MR iron quantification. Reference values: ferritin
(males) <300 ng/mL; ferritin (females) < 150 ng/mL; transferrin saturation 25–45%; iron concentration < 6 μmol/g. y = years-old; HFE = homeostatic iron
regulator gene; F = female; M = male; wt = wild-type; I = imiglucerase; T = taliglucerase; M = miglustat.
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showed a concentration of 280 μmol/g of iron in the liver, with ferritin
at 1813 ng/mL and transferrin saturation at 47.3% (RV 20–45%),
steatosis, and a heterozygous c.845G>A, p.Cys282Tyr variant in HFE
gene. The other patient with high iron levels (210 μmol/g) is a 64-year-
old female who had ferritin at 3011 ng/dL and low transferrin satura-
tion at 17.4%. There were no signs of steatosis and she doesn't harbour
any pathogenic variant in HFE gene.
4.5. Liver biopsy
Six patients with GD type I had a liver biopsy done (Fig. 1; Table 5)
when on-treatment. One patient was found to have Gaucher cells in the
liver parenchyma; One patient had atypical Gaucher cells in a cirrhotic
parenchyma with severe iron overload in hepatocytes and Kupffer cells,
and, in a subsequent biopsy, a moderately differentiated HCC [26]. Two
patients who have had mild to moderate steatosis on ultrasound had a
biopsy confirming macrovesicular steatosis – one also with evidence of
cholestasis and a few foci of inflammation, and the other with mild
haemosiderosis. Two patients had steatohepatitis with mild activity: a
27-year-old female with a BMI of 28.8 Kg/m2 who did not show any
sign of steatosis in the ultrasound, had normal serum blood glucose and
lipid profile except for a low HDL (which is expected in GD) and that
was on SRT with eliglustat at the time of the biopsy; and a 58 year-old
man had moderate-to-severe haemosiderosis of hepatocytes and
Kupffer cells, elevated triglycerides and total and LDL cholesterol, and
low HDL, albeit a normal blood glucose, and signs of steatosis in the
liver ultrasound, and that was on ERT at the time of biopsy.
Two patients with GD type I underwent liver biopsy before treat-
ment initiation. A 34-year-old female's biopsy showed bridging (stage
3) fibrosis and scattered Gaucher cells; in the other, a 20-year-old
woman, peri-sinusoidal fibrosis was noted together with high serum
AST, ALT, and γGT, and a normal liver ultrasound.
5. Discussion
For the past few decades, the liver involvement in GD has become
subject of great importance in the patients' management. It is now re-
cognised that hepatomegaly is only one of the manifestations of hepatic
compromise in GD, and more attention is needed to all the possible
comorbidities that may arise from it. In our cohort, we observed that a
significant number of patients have mildly increased markers of hepatic
and biliary damage before the treatment initiation and throughout the
clinical follow-up, indicating that a low-grade process of liver damage is
not fully corrected by the treatment. This finding resembles the study
by James et al. from when effective treatment for GD was not available
[28], in which most patients with GD had mild-to-moderate transami-
nase elevations. In more recent cohorts, these alterations have also been
found in a lesser proportion of patients [20,21]. However, the impact of
these alterations is still unclear. Nascimbeni et al. have shown that le-
vels of liver enzymes are not correlated with liver fibrosis [20]. The
contribution of chronic liver damage to the development of other
complications such as iron deposition, since chronic hepatitis and liver
disease are strongly associated with hemosiderosis [29], has not been
fully explored to date. The high frequency of patients with elevations in
γGT may also be related to the known biliary alterations caused by GD
[30] such as changes in bile composition, increased incidence of cho-
lelithiasis, or with the chronic inflammatory process that happens in the
disease [3,4,24] causing biliary damage.
A significant proportion of patients had bilirubin elevations, both
before and during treatment. Most elevated bilirubin values corre-
sponded to direct bilirubin, which points toward a biliary cause rather
than overproduction (e.g., haemolysis). It is difficult to establish a
clinical significance of this finding, It is known that GlcCer and gluco-
sylsphingosine (GlcSph) [31,32] interact with a series of transporters of
the ABC (ATP-binding cassette) family, including ABCB1 [33]; It is also
known that the bile of patients with GD is different than in the general
Fig. 1. A: Haematoxylin and eosin, 200× magnifi-
cation. Liver biopsy of patient 26B showing macro-
vesicular steatosis in approximately 5% of hepato-
cytes, as well as a small focus of mixed inflammation
(upper left corner). Fig. 1B: Haematoxylin and eosin,
400× magnification. Liver biopsy of patient 28
showing thick bridging fibrosis characteristic of
cirrhosis, as well as substitution of the local hepatic
parenchyma by moderately differentiated hepato-
cellular carcinoma cells.
Table 5
Findings in the liver biopsy.






Inflammation Steatosis Siderosis Gaucher cells Fibrosis Other findings
6 20 None – No No No Yes Perisinusoidal No
13* 27 E I(120) T(1) I(6) E(41) I(8) E
(9)
Steatohepatitis No No No No
23* 34 None – No No No Yes Bridging No
25A* 44 I [30] M(1) T(1) I(14) Mild Mild Mild Yes No Cholestasis
25B* 49 M M(11) No Mild Mild No No No
26B 56 I [30] I(69) Steatohepatitis Severe No No No
28 60 I [15] I(34) T(2) I(72) No No Severe Yes Cirrhosis HCC
30* 63 M I(12) M(22) Mild No Moderate Yes No Nuclear
glycogenosis
y = years-old; Sx = splenectomy; E = eliglustat; I = imiglucerase; M = miglustat; HCC = hepatocellular carcinoma. In patient 28, HCC was noted only in a second
biopsy, performed 9 months after the first one. *patients with normal liver enzymes; see Table 1.
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population, being composed of lower total lipid concentration and, in
some patients, high relative concentration of sphingolipids [30]; and
finally, that ABC transporters such as ABCB1 are capable of transporting
GlcCer and GlcSph [34] across cell membranes, and are modulated by
these complex lipids [33]. ABCB1 is localized at the canalicular mem-
brane contributing to the bile formation and xenobiotic excretion [35] –
it is possible that, due to ABC-mediated efflux, the higher levels of
GlcCer present in bile [36] lead to canalicular disturbances that may
cause an impaired flow of bilirubin, leading to the slightly high levels of
DB observed.
Iron homeostasis is being increasingly recognised as a key factor of
GD's pathogenesis [25]. In a recent article by Lefèbvre et al. [37], it was
reported that a local overstimulation of hepcidin related to the lower
enzymatic activity of GCase causes iron to be sequestered within
macrophages and other cell types, leading to a lower level of free iron,
transferrin-bound iron and a higher production of ferritin by the liver.
In our study, we observed that several patients with GD have high
hepatic iron levels as measured by magnetic resonance, two of the
tested patients with levels consistent with severe iron overload – whilst
in one patient it may be caused by other risk factors such as alcoholism,
steatohepatitis, and a pathogenic HFE variant, in the other patient the
only obvious risk factor is obesity, and the low transferrin value with
exceedingly high ferritin confirm the predictions by Lefèbvre et al.
Other studies have observed increase liver iron concentration in GD
patients [38], with a positive correlation with serum ferritin con-
centration. On liver biopsy, positive iron staining has been described
extensively [28,39] both in Kupffer cells and in hepatocytes, similar to
what was observed in our cohort. Data on pre- (median = 19%, n = 8
patients) and post-treatment (median = 28%, n = 13 patients) values
for serum transferrin saturation in this cohort have been described by
Koppe et al [25], with no significant difference (p = .138).
The main ultrasound finding in our cohort was steatosis, with pre-
dominance in overweight/obese patients. Our findings differ from the
Israeli cohort, which has a much lower prevalence of fatty liver and a
higher prevalence of focal lesions [40]. In the Israeli study, 500 patients
were evaluated by US, of which 39 had ultrasonographic evidence of
hepatic disease – of these, two-thirds were on ERT and one-fourth was
splenectomised. ERT is a potent inducer of weight gain due to slowing
the increased basal metabolic rate of patients before treatment [19,41];
thus, it may be difficult to establish whether the high prevalence of
steatosis is a manifestation of GD itself, a complication of its treatment,
or a comorbidity. A significant proportion of our patients had dyslipi-
daemia, which indicates that metabolic syndrome may play a role as a
confounder in the development of steatosis in these patients [42]. Re-
markably, a young patient being treated with eliglustat that had a he-
patic biopsy done during cholecystectomy was diagnosed with steato-
hepatitis, regardless of having no signs of steatosis. This case raises two
questions: whether ultrasound can be relied upon as a mean of
screening for liver disease in GD patients; and whether steatohepatitis
may be a manifestation of GD, since the only known risk factor that the
patient had for steatohepatitis (a BMI of 28.8 Kg/m2) is hardly con-
sidered enough for a sole causal factor; and, as the blood glucose and
lipid levels of this patient were normal except for a low HDL, which is a
marker of GD, dyslipidaemia and metabolic syndrome are not strongly
suspected. Another possible cause for the steatohepatitis in this patient
could be what is becoming known as “lean fatty liver disease” – that is,
non-alcoholic steatosis (NAFLD) or steatohepatitis (NASH) in patients
with few or no risk factors for such [43]. Although in the classical de-
finition of “lean NASH” the patient's BMI is normally <25 Kg/m2 [43],
despite some authors advocating for the use of a BMI of <30 Kg/m2 in
Western populations [44], it is expected that patients with “non-lean
NASH” are male, of older age, and have hypertension, insulin re-
sistance, or hypercholesterolaemia - none of which is present in this
patient [43]. It is speculated that lean NASH arises from “metabolic
obesity” in non-obese people, which is reflected by the higher dis-
tribution of fat to the visceral intraabdominal organs [44,45], along
with classical risk factors such as insulin resistance and hypercholes-
terolaemia [44] – none of which were present in this patient – and
genetic predisposition due to polymorphisms in genes associated with
lipid metabolism [44,46].
Liver fibrosis is shown to be increased in a significant proportion of
patients [20], especially in those who were splenectomised [38], and it
is a major risk factor for HCC [39]. Liver fibrosis is correlated with
increased severity of GD [20], although its correlation with biomarkers
of disease activity is still controversial [20,38]. In the pre-ERT era,
when no specific treatment for GD was available, liver fibrosis was a
common finding [28], and often culminated in a massive central area of
hypocellular fibrotic tissue [47,48] that led to portal hypertension and
other clinical manifestations of cirrhosis [28].
Cholelithiasis is a frequent comorbid process of GD with about
30–45% [49,50] lifetime incidence in these patients. Although the
causes for this increased incidence are not completely elucidated, some
authors speculate that the excretion of GlcCer in the bile may increase
its lithogenicity, predisposing to the formation of gallstones [30,36,49].
In our cohort, we have observed a similarly increased prevalence of
cholelithiasis in GD patients compared to the general population, with
12 patients affected in a total of 41.
6. Conclusion
In this study, we presented a comprehensive summary of the hepatic
manifestations in a well-characterised cohort of patients with GD,
showing that several patients have lingering alterations that may in-
dicate a smouldering process of liver damage which is not completely
avoided by standard therapy. It is also noticeable that many patients
have liver steatosis or steatohepatitis, with a noticeable increase in
prevalence during treatment with ERT, but it is still unclear whether it
reflects a consequence from the treatment, a feature of the disease, or a
coincidental finding.
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